TY  - JOUR
A1  - Schmidt, Stanislaw
A1  - Hogardt, Michael
A1  - Demir, Asuman
A1  - Röger, Frauke
A1  - Lehrnbecher, Thomas
T1  - Immunosuppressive compounds affect the fungal growth and viability of defined aspergillus species
T2  - Pathogens
N2  - Immunosuppressive drugs are administered to a number of patients; e.g., to allogeneic hematopoietic stem cell transplant recipients. Immunosuppressive drugs impair the immune system and thus increase the risk of invasive fungal disease, but may exhibit antifungal activity at the same time. We investigated the impact of various concentrations of three commonly used immunosuppressive compounds—cyclosporin A (CsA), methylprednisolone (mPRED), and mycophenolic acid (MPA)—on the growth and viability of five clinically important Aspergillus species. Methods included disc diffusion, optical density of mycelium, and viability assays such as XTT. MPA and CsA had a species-specific and dose-dependent inhibitory effect on the growth of all Aspergillus spp. tested, although growth inhibition by MPA was highest in A. niger, A. flavus and A. brasiliensis. Both agents exhibited species-specific hyphal damage, which was higher when the immunosuppressants were added to growing conidia than to mycelium. In contrast, mPRED increased the growth of A. niger, but had no major impact on the growth and viability of any of the other Aspergillus species tested. Our findings may help to better understand the interaction of drugs with Aspergillus species and ultimately may have an impact on individualizing immunosuppressive therapy.
KW  - Aspergillus species
KW  - immunosuppressive agent
KW  - mycophenolic acid
KW  - methylprednisolone
KW  - cyclosporin A
KW  - growth inhibition
KW  - viability
Y1  - 2019
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/51830
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-518309
SN  - 2076-0817
N1  - This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
VL  - 8
IS  - 4, Art. 273
SP  - 1
EP  - 12
PB  - MDPI
CY  - Basel
ER  -